Group 1 - Aikolan's controlling shareholder Liu Yi terminated the share transfer agreement for 4 million shares, which represents 5% of the company's total share capital, with no change in control [1] - Wancheng Group announced a cash dividend of 4.00 yuan per 10 shares, totaling 71.9959 million yuan, with the record date on May 19, 2025 [1] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation, acquiring a total of 7% equity in the company [2] Group 2 - China Resources Double Crane's subsidiaries received approval for two drugs, indicating progress in their product pipeline [3] - Fosun Pharma's subsidiary's drug was included in the breakthrough therapy program, highlighting its innovative potential [4] - Zhongheng Group's subsidiary received approval for naloxone injection, enhancing its product offerings [5] Group 3 - Shenzhen Airport reported a passenger throughput of 5.3202 million in April, a year-on-year increase of 23.50% [8] - Hangzhou Bank successfully issued 5 billion yuan in technology innovation bonds, aimed at supporting tech innovation [10] - Jiuzhou Pharmaceutical received approval for a raw material drug used in treating severe depression, expanding its product range [12] Group 4 - Aihua Group reported a 25.38% decline in revenue for the first four months of the year, indicating potential challenges [27] - Changhua Group received a project designation notice from a well-known new energy vehicle company, with an expected total sales amount of approximately 108 million yuan [28] - Nanchao Food reported a slight revenue decrease of 0.98% in April, reflecting market conditions [30]

近日，广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"） 的控股子公司重庆莱美药业股份有限公司（以下简称"莱美药业"）收到国家 药品监督管理局核准签发的盐酸纳洛酮注射液 1ml：1mg 和 2ml：2mg 两种规格 《药品补充申请批准通知书》，现将有关事宜公告如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 药品名称 | 通用名称：盐酸纳洛酮注射液 | | | --- | --- | --- | | | 英文名/拉丁名：Naloxone Hydrochloride | Injection | | 剂型 | 注射剂 | | | 注册分类 | 化学药品 | | | 原药品批准文号 | 国药准字 H20243819 | | | 药品注册标准编号 | YBH10252025 | | | 包装规格 | 5 支/盒、10 支/盒 | | | 规格 | 1ml：1mg | 2ml：2mg | | 通知书编号 | 2025B01940 | 2025B01941 | | 申请内容 | 药学研究信息：盐酸纳洛酮注射液新 增 ...

Core Viewpoint - 中恒集团 is focusing on enhancing its market strategies and expanding its product offerings in both the pharmaceutical and health sectors, while also exploring potential mergers and acquisitions to strengthen its position in the industry [1][2][5]. Group 1: Business Strategies - The company is implementing personalized market strategies through regional collaboration, focusing on key products like 血栓通 and 中华跌打丸 to expand its marketing and sales efforts [2]. - It aims to deepen its market penetration by developing specialized marketing teams and establishing sales channels that radiate from provincial capitals to surrounding areas [2]. - The company is leveraging new media and exhibitions to enhance brand visibility and expand its sales network [2]. Group 2: Product Development - 中恒集团 has launched 154 new health products in 2024, with 51 already in production, while continuing to promote its traditional product, 双钱龟苓膏 [3]. - The company is focusing on core health food products and expanding its sales channels to achieve growth in both pharmaceutical and health food sectors [4]. Group 3: Growth Opportunities - The company identifies several growth points, including expanding its blood thrombus product market, enhancing the coverage of its跌打丸 product, and increasing e-commerce sales [4]. - It is also innovating in the daily chemical sector and exploring international markets, particularly in Southeast Asia, through partnerships [4]. Group 4: Financial Performance - In Q1 2025, 中恒集团 reported a revenue of 742 million yuan, a year-on-year decrease of 7.92%, and a net profit of 18.27 million yuan, down 66.61% [7]. - The company's debt ratio stands at 31.89%, with a gross profit margin of 29.62% [7]. Group 5: Share Buyback - The company plans to conduct a share buyback within a range of 300 million to 500 million yuan, with the first buyback executed on April 10, 2025, totaling approximately 42.15 million shares [6].

证券代码：600252 证券简称：中恒集团 公告编号：临2025-53 广西梧州中恒集团股份有限公司 关于 2025 年以集中竞价交易方式回购公司股份 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/25 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 2 8 | 26 | 日~2025 | 年 | 月 | 25 | 日 | | 预计回购金额 | 30,000.00万元~50,000.00万元 | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 4,214.6997万股 | | | | | | | | 累计已回购股数占总股本比例 | 1.2720% | | | ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-52 广西梧州中恒集团股份有限公司 关于为控股子公司中恒中药材提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●担保人名称：广西梧州中恒集团股份有限公司（以下简称"公司"或"中 恒集团"） ●被担保人名称及是否为上市公司关联人：公司的控股子公司广西中恒中药 材产业发展有限公司（以下简称"中恒中药材"），本次担保不涉及关联担保。 ●本次担保金额及已实际为其提供的担保余额：公司本次为中恒中药材提供 的担保金额为人民币 9,999,604 元；截至本公告披露日，公司为中恒中药材实际 提供的担保余额为人民币 20,999,456 元（含本次担保）。 ●本次担保是否有反担保：否 ●对外担保逾期的累计数量：无 一、担保情况概述 （一）担保基本情况 为满足控股子公司中恒中药材日常经营和业务发展需求，确保中恒中药材 生产经营活动的顺利开展，公司为中恒中药材向金融机构申请融资提供连带责 任保证，具体情况如下： 2025 年 4 月 29 日，公司 ...

Key Points - The company has announced a share repurchase plan to buy back its A-shares at a price not exceeding 3.80 RMB per share, with a total repurchase amount between 300 million RMB and 500 million RMB [3][16][17] - As of April 29, 2025, the company has repurchased a total of 33,339,797 shares, accounting for 1.0062% of the total share capital, with a total expenditure of approximately 79.20 million RMB [17][18] - The company plans to cancel 11,065,300 shares of restricted stock that were granted but not yet unlocked due to unmet performance conditions for the year 2024 [25][46][58] - The company has received a total of 194,112,400 RMB from the sale of an 18% stake in a subsidiary, which has been fully paid [6][7] - The company has undergone personnel changes, including the resignation of a vice president and the appointment of a new securities representative [9][12][34] Financial Data - The first quarter financial report for 2025 has been approved by the board and reflects the company's financial status and operational performance [23][39] - The company reported a net profit of -330.76 million RMB for 2024, which did not meet the performance criteria set for the unlocking of restricted shares [58] Shareholder Information - The company has adjusted the purpose of repurchased shares from employee stock ownership plans to cancellation and reduction of registered capital [4][5] - The company has a total of 3,302,280,267 shares after the cancellation of the repurchased shares [25] Other Important Information - The company has agreed to a supplementary agreement regarding overdue compensation payments related to land acquisition with a local government entity [7] - The company has received interest payments totaling approximately 4.09 million RMB related to overdue compensation [7] - The company has been rated A for its safety, environmental protection, and energy-saving goals for 2024 [36]

广西梧州中恒集团股份有限公司 关于变更公司证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600252 证券简称：中恒集团 公告编号：临 2025-50 附：冯卢璐先生简历 冯卢璐，男，1987 年 4 月出生，中共党员，大学本科学历。曾任广西梧州 中恒集团股份有限公司信息披露专员、主管；现任广西梧州中恒集团股份有限 公司证券事务代表、信息披露业务经理。 证券事务代表的联系方式如下： 联系电话：0771-2742275 因工作调整原因，王坤世先生申请辞去广西梧州中恒集团股份有限公司（以 下简称"公司"或"中恒集团"）证券事务代表职务，辞去证券事务代表职务后， 王坤世先生仍在公司和控股子公司担任其他职务。公司董事会对王坤世先生在担 任证券事务代表期间对公司做出的贡献表示衷心的感谢！ 2025 年 4 月 28 日，公司召开第十届董事会第二十八次会议，会议审议通过 《广西梧州中恒集团股份有限公司关于变更证券事务代表的议案》，董事会同意 聘任冯卢璐先生为公司证券事务代表，任期自本次董事会审议通过之日起至 ...

年度社会责任报告 nummi 0 ZHONGHENG GROUP 造中华好药" 扩天健康 地址：中国 广西梧州工业园区工业大道1号 邮编：543000 Add：NO.1 Industrial Avenue,Industrial Park,Wuzhou Guangxi,P.R.China（543000） 电话（Tel）：+86 0771 2742275 官网（Web）： www.wz-zhongheng.com ZHONGHENG GROU 中恒集团股票代码：600252 莱美药业股票代码：300006 (控股公司) 关于本报告 | 特别说明 | 本报告是参照《中国企业社会责任报告指南CASS-ESG5.0》关于社 | | --- | --- | | | 会责任、可持续发展的具体要求，结合公司的实际情况编制而成。 | | | 2024年1月1日至2024年12月31日，为增强报告可比性及前瞻性, | | | 部分内容有所延伸。 | | | 本报告以广西梧州中恒集团股份有限公司为主体，详述公司及子公 | | | 司2024年度社会责任的履行情况。 | | 称谓说明 | 为方便阅读,"广西梧州中恒集团股份有限公司" ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-48 广西梧州中恒集团股份有限公司 第十届监事会第十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （一）会议审议通过《广西梧州中恒集团股份有限公司 2025 年第一季度 报告》； 经审核，监事会发表如下意见：公司 2025 年第一季度报告的编制和审议程 序符合法律、法规和《公司章程》的相关规定；内容和格式符合中国证监会和上 海证券交易所的各项规定，所包含的内容真实、准确、完整地反映公司报告期的 财务状况和主要经营情况等各方面的实际情况；未发现参与季报编制和审议的人 员有违反保密规定的行为。 本议案的具体内容详见同日在上海证券交易所网站（www.sse.com.cn）披露 的《广西梧州中恒集团股份有限公司 2025 年第一季度报告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票，回避 0 票。 （二）会议审议通过《广西梧州中恒集团股份有限公司关于回购注销部分 已授予但尚未解除限售的限制性股票的议案》。 监事会认为：鉴于公司 2024 ...

广西梧州中恒集团股份有限公司 第十届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 证券代码：600252 证券简称：中恒集团 公告编号：临 2025-47 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）第十 届董事会第二十八次会议通知和议案材料于 2025 年 4 月 24 日以电子邮件的方式 发出，会议于 2025 年 4 月 28 日以现场结合通讯方式在广西南宁市江南区高岭 路 100 号办公楼会议室召开，会议由公司董事长杨金海先生主持。会议应参加 表决董事 7 人，实际参加表决董事 7 人，独立董事陈道峰先生、龚行楚先生、 李俊华先生均以通讯方式出席会议。会议的召集和召开符合《公司法》《公司章 程》和《公司董事会议事规则》的有关规定。 二、董事会会议审议情况 会议审议并以记名投票方式表决通过以下议案及事项： （一）会议审议通过《广西梧州中恒集团股份有限公司 2025 年第一季度 报告》； 本议案的具体内容详见同日在上海证券交易所网站（www.sse. ...